報價延遲最少15分鐘:2024/12/25 02:49 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
69.91 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.09/6.39
|
|
企業價值
13.48B
|
| 資產負債 |
|
每股賬面淨值
16.46
|
| 現金流量 |
|
現金流量率
0.01
|
| 損益表 |
|
收益
3.70B
|
|
每股收益
18.73
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/25 02:49 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs. |